Mizuho sees Sarepta Therapeutics (SRPT) sell-off on elevidys death 'likely an overreaction'

Mizuho analyst Uy Ear reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) calling the sell-off on the reported Elevidys death a "likely overreaction'

The analyst commented, "While acute liver injury is a known side effect of Elevidys, this is the first case of ALF leading to death in >800 patients treated. The patient had a recent CMV infection, which can damage the liver. We continue to see Elevidys benefit/risk profile as positive."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $101.35 yesterday.

You May Also Be Interested In

• FDA Asks Novavax (NVAX) to Complete New Study for Delayed Covid-19 Shot's Approval, Sources Say -- WSJ
• Trump: We'll Be Reasonable On Tariffs, Markets are Adjusting
• Meridian Corporation (MRBK) Misses Q1 EPS by 11c